Short Interest in Alimera Sciences, Inc. (NASDAQ:ALIM) Declines By 14.6%

Alimera Sciences, Inc. (NASDAQ:ALIMGet Free Report) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 103,900 shares, a drop of 14.6% from the April 30th total of 121,700 shares. Based on an average trading volume of 67,700 shares, the short-interest ratio is presently 1.5 days.

Analyst Ratings Changes

A number of research analysts recently weighed in on ALIM shares. Maxim Group initiated coverage on shares of Alimera Sciences in a research note on Monday, March 25th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Alimera Sciences in a research note on Thursday, May 16th. Finally, StockNews.com cut Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th.

Read Our Latest Stock Analysis on Alimera Sciences

Alimera Sciences Price Performance

Shares of ALIM stock opened at $3.14 on Friday. The stock has a market cap of $164.50 million, a P/E ratio of -2.03 and a beta of 1.20. The company’s fifty day simple moving average is $3.55 and its two-hundred day simple moving average is $3.66. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71. Alimera Sciences has a 52 week low of $2.46 and a 52 week high of $4.38.

Alimera Sciences (NASDAQ:ALIMGet Free Report) last posted its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The business had revenue of $23.01 million during the quarter, compared to analysts’ expectations of $23.72 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. During the same period last year, the business posted ($0.71) earnings per share. Analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Large investors have recently added to or reduced their stakes in the stock. Ancora Advisors LLC purchased a new stake in shares of Alimera Sciences in the first quarter valued at $915,000. Hillsdale Investment Management Inc. purchased a new position in shares of Alimera Sciences during the first quarter valued at approximately $169,000. Vanguard Group Inc. boosted its position in shares of Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares during the period. Fifth Lane Capital LP bought a new position in shares of Alimera Sciences during the first quarter valued at approximately $83,000. Finally, Stonepine Capital Management LLC raised its holdings in shares of Alimera Sciences by 0.4% in the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after buying an additional 15,773 shares during the period. 99.83% of the stock is owned by institutional investors.

About Alimera Sciences

(Get Free Report)

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

See Also

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.